Synthesis of Therapeutic Agents for Treatment of Infectious Diseases

用于治疗传染病的治疗剂的合成

• 批准号: 10901810
• 负责人: MARK MIDDLETON
• 金额: $ 10万
• 依托单位: STARKS ASSOCIATES, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-02-16 至 2019-02-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10901810
• 关键词: Acquired Immunodeficiency Syndrome; Animals; Clinical Research; Communicable Diseases; Contractor; Contracts; Diagnosis; Disease; Good Manufacturing Process; HIV; Immune; Immunology; In Vitro; Local Microbicides; Mediating; Microbiology; National Institute of Allergy and Infectious Disease; Phase; Prevention; Regulation; Research; Research Support; Resources; Testing; Therapeutic; Therapeutic Agents; United States Dept. of Health and Human Services; United States National Institutes of Health; chemical synthesis; clinical diagnostics; infectious disease treatment; microbicide; vaccine development

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of AIDS has a requirement for the synthesis of therapeutics directed against HIV and other infectious diseases as well as agents to serve and anti-HIV topical microbicides. This initiative provides the resources for the synthesis of microbicides and compounds for the treatment of HIV, and other infectious diseases of relevance to the research agenda of NIAID. The contract will synthesize chemicals, in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations if necessary, in quantities needed for testing in in vitro screens, animals, or early Phase I clinical studies.

美国国家过敏和传染病研究所（NIAID），美国国立卫生研究院（NIH），卫生和人类服务部（DHHS）支持与微生物学和免疫学的基本理解相关的研究，导致疫苗，治疗和医学诊断的发展，用于预防，治疗和诊断传染病和免疫介导的疾病。 NIAID艾滋病分部需要合成针对HIV和其他传染病的治疗剂，以及用作抗HIV局部杀微生物剂的药剂。 该倡议为合成杀微生物剂和化合物提供了资源，用于治疗艾滋病毒和与NIAID研究议程相关的其他传染病。 该合同将根据FDA现行的良好生产规范（cGMP）规定合成化学品，如有必要，其数量将用于体外筛选，动物或早期I期临床研究。